Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours

BACKGROUND: Patients with metastatic small-intestinal neuroendocrine tumours (NET) have been shown to have a reduced quality of life compared to the general population and many have disabling symptoms during somatostatin analogue (SSA) treatment. The aim of this prospective study was to document the...

Descripción completa

Detalles Bibliográficos
Autores principales: Sorbye, Halfdan, Meyer, Liv Sylvi, Mordal, Kjersti Elisabeth, Myhre, Simen, Thiis-Evensen, Espen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298767/
https://www.ncbi.nlm.nih.gov/pubmed/32546236
http://dx.doi.org/10.1186/s12955-020-01452-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298767/
https://www.ncbi.nlm.nih.gov/pubmed/32546236
http://dx.doi.org/10.1186/s12955-020-01452-7

Ejemplares similares